SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Achilles Therapeutics plc (ACHL) .
Criteria proven by this page:
- VALUE (90/100, Pass) — analyst target implies upside (+35.1%).
- Analyst consensus target $2.00 (+35.1% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 46/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
90/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ACHL
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-1.74
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$2.00 (+35.1%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2018 |
$-12.69 |
$0.00 |
$-6.89M |
- |
| 2019 |
$-8.52 |
$0.00 |
$-13.99M |
- |
| 2020 |
$-0.82 |
$0.00 |
$-33.2M |
- |
| 2021 |
$-2.13 |
$0.00 |
$-61.1M |
- |
| 2022 |
$-1.82 |
$0.00 |
$-71.18M |
- |
| 2023 |
$-1.74 |
$0.00 |
$-69.67M |
- |
